92 related articles for article (PubMed ID: 29259349)
21. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
Ladányi A; Kapuvári B; Papp E; Tóth E; Lövey J; Horváth K; Gődény M; Remenár É
Head Neck; 2019 May; 41(5):1237-1245. PubMed ID: 30548478
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
23. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
24. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
[TBL] [Abstract][Full Text] [Related]
25. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
[TBL] [Abstract][Full Text] [Related]
27. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
Le Tourneau C; Siu LL
Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.
Holguin F; Rubió-Casadevall J; Saigi M; Marruecos J; Taberna M; Tobed M; Maños M; Mesía R
J Chemother; 2017 Oct; 29(5):310-313. PubMed ID: 27380218
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.
Yamatodani T; Ekblad L; Kjellén E; Johnsson A; Mineta H; Wennerberg J
J Cancer Res Clin Oncol; 2009 Mar; 135(3):395-402. PubMed ID: 18813952
[TBL] [Abstract][Full Text] [Related]
31. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
32. The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial-like head and neck carcinoma subtypes.
Pavón MA; Arroyo-Solera I; León X; Téllez-Gabriel M; Virós D; Gallardo A; Céspedes MV; Casanova I; Lopez-Pousa A; Barnadas A; Quer M; Mangues R
Head Neck; 2019 Jun; 41(6):1830-1845. PubMed ID: 30652380
[TBL] [Abstract][Full Text] [Related]
33. A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.
Becher F; Ciccolini J; Imbs DC; Marin C; Fournel C; Dupuis C; Fakhry N; Pourroy B; Ghettas A; Pruvost A; Junot C; Duffaud F; Lacarelle B; Salas S
Sci Rep; 2017 Jun; 7(1):2714. PubMed ID: 28578404
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy.
Sernicola A; Lampitelli S; Marraffa F; Maddalena P; Grassi S; Richetta AG; Calvieri S
F1000Res; 2019; 8():933. PubMed ID: 32047600
[TBL] [Abstract][Full Text] [Related]
35. Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab.
Berliner JG; Schulman JM; Lazarova Z; Olasz E; Arron ST
Dermatol Surg; 2019 Feb; 45(2):313-316. PubMed ID: 29957662
[No Abstract] [Full Text] [Related]
36. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.
Chong LC; Twa DD; Mottok A; Ben-Neriah S; Woolcock BW; Zhao Y; Savage KJ; Marra MA; Scott DW; Gascoyne RD; Morin RD; Mungall AJ; Steidl C
Blood; 2016 Sep; 128(9):1206-13. PubMed ID: 27268263
[TBL] [Abstract][Full Text] [Related]
37. Targeting fusions for improved outcomes in oncology treatment.
Nikanjam M; Okamura R; Barkauskas DA; Kurzrock R
Cancer; 2020 Mar; 126(6):1315-1321. PubMed ID: 31794076
[TBL] [Abstract][Full Text] [Related]
38. Growth Factor Receptor Fusions Predict Therapeutic Sensitivity.
Ahluwalia MS; Rich JN
Clin Cancer Res; 2015 Jul; 21(14):3105-7. PubMed ID: 25995339
[TBL] [Abstract][Full Text] [Related]
39. Pan-cancer analysis reveals multifaceted roles of retrotransposon-fusion RNAs.
Lee B; Park J; Voshall A; Maury E; Kang Y; Kim YJ; Lee JY; Shim HR; Kim HJ; Lee JW; Jung MH; Kim SC; Chu HBK; Kim DW; Kim M; Choi EJ; Hwang OK; Lee HW; Ha K; Choi JK; Kim Y; Choi Y; Park WY; Lee EA
bioRxiv; 2023 Oct; ():. PubMed ID: 37905014
[TBL] [Abstract][Full Text] [Related]
40. The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression.
Powers MP
Oncogene; 2019 Nov; 38(47):7197-7199. PubMed ID: 31616060
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
